Search PubMed⌕ Search

Biomedical subjects

C Schyvens

Publications and source records attributed to C Schyvens.

3 recordsLinked to original sources

Characterization of the P2 receptors in rabbit pulmonary artery.

1. We have identified the P2 receptors mediating vasomotor responses in the rabbit pulmonary artery. 2. Neither ATP nor UTP contracted intact or endothelium-denuded rings. However, both relaxed intact rings of rabbit pulmonary artery that had been preconstricted with phenylephrine (pD2 5.2 and 5.6, respectively). 3. The vasodilator effect of UTP was endothelium-dependent and abolished by the nitric oxide synthase inhibitor NG-nitro-L-arginine (L-NOARG). 4. The vasodilator effect of ATP was only partially inhibited by removal of endothelium or addition of L-NOARG, suggesting an additional direct effect on vascular smooth muscle. 5. The endothelium-dependent vasodilator responses to UTP and ATP were competitively antagonized by suramin. 6. Preconstricted, endothelium-denuded rings were also relaxed by 2-methylthio ATP (pD2 6.6), a P2Y receptor agonist. 7. Ca(2+)-mobilizing P2U receptors were identified on smooth muscle cells on the basis of single cell responses to ATP (pD2 7.8) and UTP (pD2 7.9; 6.7 in the presence of 100 microM suramin). 8. There was no evidence of a Ca(2+)-mobilizing P2Y receptor in these cultured cells. 9. The data suggest the presence of (i) a suramin-sensitive P2U receptor on endothelial cells that induces vasorelaxation through NO release, (ii) a suramin-sensitive P2U receptor on cultured smooth muscle cells that mobilizes Ca2+ but is not coupled to vasomotor responses and (iii) a putative P2Y receptor on vascular smooth muscle cells that induces relaxation via a Ca(2+)-independent signal transduction pathway.

Adenosine Triphosphate↗

The role of nitric oxide in heart failure. Potential for pharmacological intervention.

There is now considerable evidence that nitric oxide (NO) production and action are abnormal in patients with heart failure. Spontaneous NO release from the vascular endothelium is preserved or enhanced in patients with heart failure and this may help to maintain tissue perfusion by blunting the vasoconstriction induced by various neurohumoral factors. On the other hand, endothelial NO release in response to various stimuli including exercise appears to be diminished and this may contribute to the impaired exercise capacity of patients with heart failure. It is now apparent that NO produced within the heart plays an important role in the modulation of cardiac contractility under physiological conditions. In patients with heart failure, however, increased myocardial NO production in response to cytokines such as tumour necrosis factor-alpha may contribute to reduced contractility and myocyte injury. Our understanding of the role of NO in the control of vascular tone has provided an explanation for the efficacy of nitrovasodilators in heart failure and has stimulated novel approaches to augmenting endogenous vascular NO production. There is also evidence that ACE inhibitors act to restore normal endothelial function in patients with heart failure. Increased NO production within the heart, particularly that produced via the pro-inflammatory inducible NO synthase, may be detrimental. It remains to be determined whether selective inhibition of inducible NO synthase can favourably modify the course of this lethal condition.

Angiotensin-Converting Enzyme Inhibitors↗

Brachioradial delay.

Explore the source record for details and available documents.

Aortic Valve Stenosis↗